文献速递乳房整形与再造美容整形

跨性别女性与顺性别女性乳房增大术的技术与临床差异

Technical and Clinical Differences Between Transgender and Cisgender Females Undergoing Breast Augmentation.
PubMed 文献 · Ann Plast Surg · 2023-09-23

本研究为2009至2019年单中心回顾性队列,纳入250例顺性别女性与153例跨性别女性原发性乳房增大术患者。跨性别组吸烟、免疫抑制、肥胖、精神障碍及高血压比例更高,乳房基底宽度、胸骨切迹至乳头距离及假体体积更大,手术部位感染发生率更高(3.9% vs 0.4%,P<0.013)。再入院、再手术及并发症率两组相似,包膜挛缩为两组最常见并发症及再手术指征。

要点

  • 跨性别女性乳房增大术在解剖、临床与技术方面与顺性别女性美容性乳房增大术存在重要差异。
  • 跨性别组假体体积中位数500 mL(四分位距425-600 mL),大于顺性别组350 mL(四分位距325-385 mL),P<0.0001。
  • 跨性别组手术部位感染发生率3.9%,高于顺性别组0.4%,P<0.013。

核心结论

  • 跨性别女性重建性性别肯定乳房增大术与顺性别女性美容性乳房增大术之间存在重要的解剖、临床与技术差异。
  • 性别肯定外科医生必须了解这些差异,以提供最佳质量的照护并帮助患者实现性别认同与身体意象之间更好的 congruity。

研究设计与样本

  • 回顾性队列研究,纳入2009年至2019年在专为跨性别照护的三级中心接受原发性乳房增大术的患者。
  • 排除乳房固定术、二次增大术及重建手术;从医疗记录收集人口学、手术及临床数据;所有患者术后至少随访1年;采用双变量分析。

主要发现

  • 共纳入250例顺性别女性和153例跨性别女性。
  • 跨性别组吸烟(P<0.0001)、免疫抑制(P<0.0001)、肥胖(P<0.0001)、精神障碍(P<0.0001)及高血压(P=0.002)比例更高。
  • 跨性别组乳房基底宽度中位数(P<0.0001)、胸骨切迹至乳头距离(P<0.0001)及假体体积(500 mL [四分位距425-600 mL] vs 350 mL [四分位距325-385 mL];P<0.0001)更大。
  • 跨性别组假体体积与体表面积相关性更强(r=0.71,P<0.0001)。
  • 再入院、再手术及并发症率两组相似;但跨性别组手术部位感染发生率更高(3.9% vs 0.4%,P<0.013);包膜挛缩为两组最常见并发症及再手术指征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gender-affirming surgery is a quickly expanding field. However, it is facing a shortage of specialized surgeons for a population exceeding 1.4 million individuals. Many studies comparing outcomes between cisgender and transgender patients fail to describe the technical differences of the operation. Breast augmentation in the transgender female patient involves important anatomical, technical, and clinical features that differ from the cisgender female. In this study, we aimed to describe and compare these characteristics between these 2 groups to better inform the new generation of gender-affirming surgeons. METHODS: A retrospective cohort study of patients who underwent primary breast augmentation between 2009 and 2019 at a specialized tertiary center for transgender care was performed. Mastopexy, secondary augmentation, and reconstructive procedures were excluded. Demographic, operative, and clinical data were collected from medical records. All patients had a minimum of 1 year of follow-up after the initial surgery. Bivariate analysis was performed. RESULTS: A total of 250 cisgender females and 153 transgender females were included. The transgender group showed higher rates of smoking ( P < 0.0001), immunosuppression ( P < 0.0001), obesity ( P < 0.0001), mental health disorders ( P < 0.0001), and hypertension ( P = 0.002). Median base width ( P < 0.0001), sternal notch to nipple distance ( P < 0.0001), and implant size (500 mL [interquartile range, 425-600 mL] vs 350 mL [interquartile range, 325-385 mL]; P < 0.0001) were larger in transgender patients. Transgender patients also demonstrated a stronger correlation between implant size and body surface area ( r = 0.71, P < 0.0001). Readmission, reoperation, and complication rates were similar between the groups; however, transgender females had a higher incidence of surgical site infections (3.9% vs 0.4%, P < 0.013). Capsular contracture was the most common complication and indication for reoperation in both groups. CONCLUSIONS: There are important anatomical, clinical, and technical differences between reconstructive gender-affirming breast augmentation in transgender female patients and cosmetic breast augmentation in the cisgender female. The gender-affirming surgeon must know these differences to provide the best quality of care and help patients achieve better congruence between their gender identity and body image.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Torres Perez-Iglesias CA, Heyman A, Koh DJ, et al. Technical and Clinical Differences Between Transgender and Cisgender Females Undergoing Breast Augmentation. Ann Plast Surg. 2023. PMID: 37823620. doi:10.1097/SAP.0000000000003706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。